BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee MH, Lu SN, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L’Italien G, Chen CJ. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One. 2014;9:e94760. [PMID: 24801353 DOI: 10.1371/journal.pone.0094760] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Yu ML. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol 2016;64:981-2. [PMID: 26795827 DOI: 10.1016/j.jhep.2015.12.022] [Reference Citation Analysis]
2 Huang CF, Huang CY, Yeh ML, Wang SC, Chen KY, Ko YM, Lin CC, Tsai YS, Tsai PC, Lin ZY, Chen SC, Dai CY, Huang JF, Chuang WL, Yu ML. Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment. EBioMedicine 2017;15:81-9. [PMID: 27998720 DOI: 10.1016/j.ebiom.2016.11.031] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
3 Goossens N, Hoshida Y. Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin Liver Dis (Hoboken) 2015;5:132-5. [PMID: 26213619 DOI: 10.1002/cld.483] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
4 Liu J, Tseng T, Yang H, Lee M, Batrla-utermann R, Jen C, Lu S, Wang L, You S, Chen P, Chen C, Kao J. Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System. Journal of Infectious Diseases 2015;211:1566-73. [DOI: 10.1093/infdis/jiu659] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
5 Kubota N, Fujiwara N, Hoshida Y. Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. J Clin Med 2020;9:E3843. [PMID: 33256232 DOI: 10.3390/jcm9123843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 198] [Cited by in F6Publishing: 196] [Article Influence: 39.6] [Reference Citation Analysis]
7 Duarte-Salles T, Misra S, Stepien M, Plymoth A, Muller D, Overvad K, Olsen A, Tjønneland A, Baglietto L, Severi G, Boutron-Ruault MC, Turzanski-Fortner R, Kaaks R, Boeing H, Aleksandrova K, Trichopoulou A, Lagiou P, Bamia C, Pala V, Palli D, Mattiello A, Tumino R, Naccarati A, Bueno-de-Mesquita HB, Peeters PH, Weiderpass E, Quirós JR, Agudo A, Sánchez-Cantalejo E, Ardanaz E, Gavrila D, Dorronsoro M, Werner M, Hemmingsson O, Ohlsson B, Sjöberg K, Wareham NJ, Khaw KT, Bradbury KE, Gunter MJ, Cross AJ, Riboli E, Jenab M, Hainaut P, Beretta L. Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population. Cancer Prev Res (Phila) 2016;9:758-65. [PMID: 27339170 DOI: 10.1158/1940-6207.CAPR-15-0434] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
8 Chen CJ, You SL, Hsu WL, Yang HI, Lee MH, Chen HC, Chen YY, Liu J, Hu HH, Lin YJ, Chu YJ, Huang YT, Chiang CJ, Chien YC. Epidemiology of Virus Infection and Human Cancer. Recent Results Cancer Res 2021;217:13-45. [PMID: 33200360 DOI: 10.1007/978-3-030-57362-1_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Chien TL, Hsiao FY, Chen LJ, Wen YW, Lin SW. Development and Validation of a Risk Scoring System for Cephamycin-Associated Hemorrhagic Events. Sci Rep 2019;9:12905. [PMID: 31501462 DOI: 10.1038/s41598-019-49340-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10:681-701. [PMID: 27229718 DOI: 10.1007/s12072-016-9736-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
11 Li TC, Li CI, Liu CS, Lin WY, Lin CH, Yang SY, Lin CC. Risk score system for the prediction of hepatocellular carcinoma in patients with type 2 diabetes: Taiwan Diabetes Study.Semin Oncol. 2018;45:264-274. [PMID: 30342872 DOI: 10.1053/j.seminoncol.2018.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Goossens N, Nakagawa S, Hoshida Y. Molecular prognostic prediction in liver cirrhosis. World J Gastroenterol 2015; 21(36): 10262-10273 [PMID: 26420954 DOI: 10.3748/wjg.v21.i36.10262] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kang N, Chung JW, Jang ES, Jeong SH, Kim JW. Computed Tomography-Measured Liver Volume Predicts the Risk of Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients. Dig Dis Sci 2021. [PMID: 33630218 DOI: 10.1007/s10620-020-06762-w] [Reference Citation Analysis]
14 Huang TS, Lin CL, Lu MJ, Yeh CT, Liang KH, Sun CC, Shyu YC, Chien RN. Diabetes, hepatocellular carcinoma, and mortality in hepatitis C-infected patients: A population-based cohort study. J Gastroenterol Hepatol. 2017;32:1355-1362. [PMID: 27930829 DOI: 10.1111/jgh.13670] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
15 Wei MT, Le MH, Landis C, Trinh H, Wong G, Le A, Zhang J, Cheung R, Nguyen MH. Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C. J Med Virol 2021. [PMID: 34219250 DOI: 10.1002/jmv.27168] [Reference Citation Analysis]
16 Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep 2017;16:64-71. [PMID: 28337405 DOI: 10.1007/s11901-017-0336-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
17 Huang C, Dai C, Yeh M, Huang C, Tai C, Hsieh M, Liang P, Lin Y, Hsieh M, Yang H, Huang J, Lin Z, Chen S, Yu M, Chuang W. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. Journal of Hepatology 2015;62:512-8. [DOI: 10.1016/j.jhep.2014.10.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
18 Chang IC, Huang SF, Chen PJ, Chen CL, Chen CL, Wu CC, Tsai CC, Lee PH, Chen MF, Lee CM, Yu HC, Lo GH, Yeh CT, Hong CC, Eng HL, Wang J, Tseng HH, Hsiao CH, Wu HI, Yen TC, Liaw YF. The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer Network. Medicine (Baltimore) 2016;95:e3284. [PMID: 27082566 DOI: 10.1097/MD.0000000000003284] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
19 Su TH, Liu CJ, Tseng TC, Chou SW, Liu CH, Yang HC, Wu SJ, Chen PJ, Chen DS, Chen CL. Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study. Hepatology. 2016;63:721-730. [PMID: 26662347 DOI: 10.1002/hep.28387] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
20 Konerman MA, Brown M, Zheng Y, Lok AS. Dynamic prediction of risk of liver-related outcomes in chronic hepatitis C using routinely collected data. J Viral Hepat 2016;23:455-63. [PMID: 26893198 DOI: 10.1111/jvh.12509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
21 Ganne-Carrié N, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, de Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Trinchet JC, Nahon P, Roudot-Thoraval F; ANRS CO12 CirVir Study Group. Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology 2016;64:1136-47. [PMID: 27348075 DOI: 10.1002/hep.28702] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
22 Chen CJ, Lee MH, Liu J, Yang HI. Hepatocellular carcinoma risk scores: ready to use in 2015? Hepat Oncol 2015;2:1-4. [PMID: 30190979 DOI: 10.2217/hep.14.32] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]